Repligen
RGEN
NZ$210.24
Share price
4.72%
Change (1 day)
-10.08%
Change (1 year)
Categories
Repligen (RGEN) - Total assets
Total assets on the balance sheet as of March 2025 : NZ$4.78 Billion
According to Repligen 's latest financial reports the company's total assets are NZ$4.78 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Repligen - Total assets on balance sheet (from 2001 to 2025)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2024-12-31 | NZ$5.01 B | 12.07% |
| 2023-12-31 | NZ$4.47 B | 12.28% |
| 2022-12-31 | NZ$3.98 B | 15.49% |
| 2021-12-31 | NZ$3.45 B | 30.92% |
| 2020-12-31 | NZ$2.63 B | 26.86% |
| 2019-12-31 | NZ$2.07 B | 80.02% |
| 2018-12-31 | NZ$1.15 B | 10.31% |
| 2017-12-31 | NZ$1.04 B | 151% |
| 2016-12-31 | NZ$0.41 B | 95.21% |
| 2015-12-31 | NZ$0.21 B | 30.49% |
| 2014-12-31 | NZ$0.16 B | 13.41% |
| 2013-12-31 | NZ$0.14 B | 22.43% |
| 2012-12-31 | NZ$0.11 B | |
| 2011-03-31 | NZ$95.03 M | -5.82% |
| 2010-03-31 | NZ$0.10 B | -22.43% |
| 2009-03-31 | NZ$0.13 B | 51.92% |
| 2008-03-31 | NZ$85.62 M | 110.73% |
| 2007-03-31 | NZ$40.63 M | -14.01% |
| 2006-03-31 | NZ$47.25 M | 21.76% |
| 2005-03-31 | NZ$38.8 M | -12.53% |
| 2004-03-31 | NZ$44.36 M | -8.31% |
| 2003-03-31 | NZ$48.38 M | -26.75% |
| 2002-03-31 | NZ$66.05 M | -18.4% |
| 2001-03-31 | NZ$80.95 M |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Novavax NVAX | NZ$2.16 B | -54.67% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | NZ$11.99 B | 150.58% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | NZ$6.18 B | 29.30% | 🇺🇸 USA |
 General Electric GE | NZ$208.26 B | 4,251.93% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | NZ$166.18 B | 3,372.52% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$155.08 B | 3,140.62% | 🇺🇸 USA |
 Pfizer PFE | NZ$349.05 B | 7,193.75% | 🇺🇸 USA |
 Bio-Techne TECH | NZ$4.43 B | -7.29% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | NZ$0.14 B | -96.98% | 🇺🇸 USA |
 Charles River Laboratories
CRL | NZ$12.72 B | 165.85% | 🇺🇸 USA |